Endpoints News
Disc Medicine claims PhII win for repurposed ex-Roche drug in rare blood disorder
When Disc Medicine closed a $62.5 million raise led by Bain Capital earlier this year, the biotech’s CEO John Quisel pointed to the stream of clinical readouts in blood disorders it is expecting as the impetus. Now, it’s outlining the first of those data — with an open-label Phase II trial providing what it calls
More